Cure8 research brief
Why This Matters
A national pediatric IBD registry from Colombia summarizes diagnosis age, disease types, treatment patterns (including rising biologic use), and outcomes—information that can inform families and clinicians about regional presentation and care trends.
Who Should Pay Attention
Pediatric IBD patients and caregivers; pediatric gastroenterologists and clinicians in Latin America; researchers interested in IBD epidemiology and health disparities.
Study Snapshot
What To Know
This article describes the creation and findings of a Colombian pediatric IBD registry covering children aged 0–18 years from 1999–2021.
The registry includes 209 patients and reports diagnosis age, phenotype breakdown (ulcerative colitis, Crohn’s disease, unclassifiable IBD, colonic Crohn’s, atypical UC), time to diagnosis, initial treatments, rates of biologic use over time, relapse, and remission.
The report highlights regional patterns and disparities (for example, a notable proportion from a coffee-cultivation zone) and documents common initial therapies used in this cohort: mesalamine with or without steroids, immunomodulators with or without steroids, enteral nutrition, and biologics. Biologic use increased during follow-up.
Keep In Mind
Registry data are observational and descriptive; the article provides an abstract-level summary of methods and findings rather than detailed randomized trial evidence.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.